Ceptyr ceptyr.com


Public lists: Pharma Startups (4732)

CEPTYR, Inc., was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored domain in pharmaceutical development. The company's first disease targeted is diabetes and obesity.

CEPTYR, Inc., was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored domain in pharmaceutical development. The company's first disease targeted is diabetes and obesity.

Company (Alive / Active)

Phone: 425-825-3300

Fax:

12277 134th Court NE
Suite 100
Redmond, 98052
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Ceptyr $11.5M Jul 19, 1999
See all 17 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Ceptyr Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Humanetics Corporation

Minneapolis, Minnesota, United States
Alive / ActiveHumanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.Login to see details

PlantForm Corporation

Guelph, Ontario, Canada
Alive / ActivePlantForm Corp is a new company focused on providing low cost therapeutic drugs for the improvement of quality of life. Established in early 2008 the company will use technology licensed from the University of Guelph to manufacture antibody and protein drugs in tobacco plants. The company's first product will be a biosimilar version of the breast cancer drug Herceptin. The world market in 2007 for this product was $1.7 billion and is anticipated to plateau at $3 billion in 2014 when PlantForm's ...Show allLogin to see details
See all 17 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)